- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Kathleen Lokay: Clinical Pathways Can Prevent Prior Authorization Delays
Clinical pathways can help providers avoid delays with prior authorization by ensuring that all the necessary information is there, explained Kathleen Lokay, president and CEO of Via Oncology.
Clinical pathways can help providers avoid delays with prior authorization by ensuring that all the necessary information is there, explained Kathleen Lokay, president and CEO of Via Oncology.
Transcript
How can pathways programs assist physicians who face prior authorization delays?
The challenge with prior authorization is the idea that oftentimes what your picking for the patient might be the right thing, but it’s all the information that has to be provided that is necessary to get it paid for. So, it’s rarely that the treatment itself is not eligible for prior authorization, but that the information is lacking.
One of the way we try to support folks with clinical pathways is by providing all that clinical information to the staff who actually seek the prior authorization. By getting the right information into the prior authorization into the portal the first time, then the likelihood of getting the prior authorization and having it go through successfully initially is much higher as opposed to finding out a week or a month or 6 months later that you didn’t give all the information and therefore your prior authorization didn’t go through and you’ve got a denial on your hands.
So that’s one of the key ways we see decision support really helping with prior authorization is by providing that critical clinical data.
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Neurologists Share Tips for Securing Patient Access to Gene Therapies
March 19th 2025Tenacious efforts at every level, from the individual clinician to the hospital to the state to Congress, will be needed to make sure patients can access life-saving gene therapies for neuromuscular diseases.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
EMBARK Data Show Continued Improvements With DMD Gene Therapy
March 19th 2025Data from the EMBARK trial of delandistrogene moxeparvovec in patients with Duchenne muscular dystrophy (DMD) show that benefits in functional outcomes, gene expression, and muscle imaging persist 2 years after receiving the gene therapy.
Read More
How Access to SMA Treatment Varies Globally and by Insurance Type
March 18th 2025Posters presented at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference show that therapeutic advances in treating spinal muscular atrophy (SMA) are not uniformly making it into the hands of patients who could benefit.
Read More
